• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助化疗改善膀胱癌的免疫抑制微环境并提高免疫检查点阻断的敏感性。

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade.

机构信息

Department of Oncology, Army Medical Center, Chongqing 400042, China.

Department of Urology, Army Medical Center, Chongqing 400042, China.

出版信息

J Immunol Res. 2022 Jul 21;2022:9962397. doi: 10.1155/2022/9962397. eCollection 2022.

DOI:10.1155/2022/9962397
PMID:35915657
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9338739/
Abstract

Although tumor immune microenvironment plays an important role in antitumor therapy, few studies explored the gene signatures associated with the tumor immune microenvironment of bladder cancer after neoadjuvant chemotherapy. We examined and analyzed differentially expressed genes from 9 patients with stage I-III bladder cancer by RNA immune-oncology profiling platform. After neoadjuvant chemotherapy, the expressions of 43 genes in 19 pathways and 10 genes in 5 pathways were upregulated and downregulated, respectively. Neoadjuvant chemotherapy also promoted the expression of genes related to the activation of antitumor immune responses and decreased the expression of genes related to tumor proliferation pathways. In addition, neoadjuvant chemotherapy improved tumor response to immune checkpoint blockade. Furthermore, this study also identified several genes that can be used to predict the efficacy of neoadjuvant chemotherapy and their possible molecular mechanisms. In conclusion, neoadjuvant chemotherapy may promote the activation of antitumor effects, improve the suppressive tumor immune microenvironment, and increase the sensitivity of bladder cancer to immune checkpoint blockade.

摘要

尽管肿瘤免疫微环境在抗肿瘤治疗中起着重要作用,但很少有研究探讨新辅助化疗后膀胱癌肿瘤免疫微环境相关的基因特征。我们通过 RNA 免疫肿瘤学分析平台,对 9 例 I-III 期膀胱癌患者的差异表达基因进行了检测和分析。新辅助化疗后,19 条通路中的 43 个基因和 5 条通路中的 10 个基因分别上调和下调。新辅助化疗还促进了与抗肿瘤免疫反应激活相关的基因表达,降低了与肿瘤增殖途径相关的基因表达。此外,新辅助化疗提高了肿瘤对免疫检查点阻断的反应。此外,本研究还鉴定了一些可用于预测新辅助化疗疗效及其可能的分子机制的基因。总之,新辅助化疗可能会促进抗肿瘤作用的激活,改善抑制性肿瘤免疫微环境,并增加膀胱癌对免疫检查点阻断的敏感性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f0a/9338739/79ab67c6dac7/JIR2022-9962397.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f0a/9338739/23a70bff08c7/JIR2022-9962397.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f0a/9338739/e8632817b0c1/JIR2022-9962397.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f0a/9338739/ae7fcc235401/JIR2022-9962397.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f0a/9338739/79ab67c6dac7/JIR2022-9962397.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f0a/9338739/23a70bff08c7/JIR2022-9962397.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f0a/9338739/e8632817b0c1/JIR2022-9962397.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f0a/9338739/ae7fcc235401/JIR2022-9962397.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f0a/9338739/79ab67c6dac7/JIR2022-9962397.004.jpg

相似文献

1
Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade.新辅助化疗改善膀胱癌的免疫抑制微环境并提高免疫检查点阻断的敏感性。
J Immunol Res. 2022 Jul 21;2022:9962397. doi: 10.1155/2022/9962397. eCollection 2022.
2
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer.基于表达谱的亚型可预测肌层浸润性膀胱癌对新辅助免疫检查点抑制剂的病理反应。
Nat Commun. 2023 Apr 27;14(1):2126. doi: 10.1038/s41467-023-37568-9.
3
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.新辅助免疫治疗在膀胱癌中的作用及结果。
Eur Urol Oncol. 2020 Dec;3(6):728-738. doi: 10.1016/j.euo.2020.06.009. Epub 2020 Nov 8.
4
Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.基于微环境免疫类型和程序性死亡受体配体1(PD-L1)的基因组分层,用于定制膀胱癌的治疗策略。
BMC Cancer. 2021 May 31;21(1):646. doi: 10.1186/s12885-021-08350-1.
5
Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.将血管生成signature 和肿瘤突变负担整合起来,以改善免疫检查点阻断治疗肌肉浸润性膀胱癌患者的分层。
Urol Oncol. 2023 Oct;41(10):433.e9-433.e18. doi: 10.1016/j.urolonc.2023.07.006. Epub 2023 Aug 23.
6
NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.NKG2A 和 PD-L1 表达谱预测辅助化疗和 PD-L1 阻断在肌层浸润性膀胱癌中的临床获益。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-004569.
7
Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer.NCOR1 突变对膀胱癌患者免疫微环境和免疫检查点抑制剂疗效的影响。
Front Immunol. 2021 Mar 8;12:630773. doi: 10.3389/fimmu.2021.630773. eCollection 2021.
8
CD8 T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer.CD8 T 效应细胞和免疫检查点标志物可预测膀胱癌的预后和对免疫治疗的反应性。
Oncogene. 2021 Oct;40(43):6223-6234. doi: 10.1038/s41388-021-02019-6. Epub 2021 Sep 22.
9
Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy interferon-alpha response in muscle-invasive bladder cancer.预测免疫检查点阻断治疗干扰素-α反应对肌层浸润性膀胱癌的预后和临床疗效。
Pathol Oncol Res. 2023 Apr 4;29:1611117. doi: 10.3389/pore.2023.1611117. eCollection 2023.
10
Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer.新辅助 PD-1 阻断联合化疗可诱导临床 III 期胃癌获得高病理完全缓解率和抗肿瘤免疫亚群。
Oncoimmunology. 2022 Oct 14;11(1):2135819. doi: 10.1080/2162402X.2022.2135819. eCollection 2022.

引用本文的文献

1
Development and validation of machine learning-based diagnostic models using blood transcriptomics for early childhood diabetes prediction.基于血液转录组学的机器学习诊断模型用于幼儿糖尿病预测的开发与验证。
Front Med (Lausanne). 2025 Jul 16;12:1636214. doi: 10.3389/fmed.2025.1636214. eCollection 2025.
2
Prediction of response to neoadjuvant chemotherapy in patients with muscle-invasive urothelial bladder cancer: role of immune-related gene expression.肌层浸润性尿路上皮膀胱癌患者对新辅助化疗反应的预测:免疫相关基因表达的作用
Cancer Immunol Immunother. 2025 Jul 30;74(9):279. doi: 10.1007/s00262-025-04135-8.
3

本文引用的文献

1
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.三阴性乳腺癌的免疫表型和新辅助治疗反应。
Clin Cancer Res. 2021 Oct 1;27(19):5365-5375. doi: 10.1158/1078-0432.CCR-21-0144.
2
Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy.基于肿瘤免疫微环境的膀胱癌分类以提高免疫治疗的反应率
Mol Ther Oncolytics. 2021 Feb 4;20:410-421. doi: 10.1016/j.omto.2021.02.001. eCollection 2021 Mar 26.
3
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.
Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis.
三周期与四周期新辅助化疗治疗肌层浸润性膀胱癌的系统评价与荟萃分析。
Ann Med. 2023;55(2):2281654. doi: 10.1080/07853890.2023.2281654. Epub 2023 Nov 14.
肿瘤免疫微环境与免疫评分在癌症预后和治疗疗效中的作用
Nat Rev Cancer. 2020 Nov;20(11):662-680. doi: 10.1038/s41568-020-0285-7. Epub 2020 Aug 4.
4
Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.新辅助治疗的胰腺导管腺癌患者的肿瘤微环境免疫反应。
J Natl Cancer Inst. 2021 Feb 1;113(2):182-191. doi: 10.1093/jnci/djaa073.
5
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.欧洲泌尿外科学会肌层浸润性和转移性膀胱癌指南:2020 年指南摘要。
Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29.
6
Characterization of the immune microenvironment in brain metastases from different solid tumors.不同实体瘤脑转移中免疫微环境的特征分析
Cancer Med. 2020 Apr;9(7):2299-2308. doi: 10.1002/cam4.2905. Epub 2020 Feb 4.
7
Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.新辅助治疗通过耗竭促肿瘤免疫细胞重塑胰腺癌微环境。
Clin Cancer Res. 2020 Jan 1;26(1):220-231. doi: 10.1158/1078-0432.CCR-19-1864. Epub 2019 Oct 4.
8
CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4 T-Cell-Dependent Control of Senescence.CXCR6 通过促进自然杀伤 T 细胞和 CD4 T 细胞依赖的衰老控制来抑制肝癌发生。
Gastroenterology. 2019 May;156(6):1877-1889.e4. doi: 10.1053/j.gastro.2019.01.247. Epub 2019 Jan 30.
9
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.肿瘤进展过程中髓源性抑制细胞(MDSCs)介导的免疫抑制。
Br J Cancer. 2019 Jan;120(1):16-25. doi: 10.1038/s41416-018-0333-1. Epub 2018 Nov 9.
10
Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.人 CD96 与自然杀伤细胞耗竭相关,并可预测人肝细胞癌的预后。
Hepatology. 2019 Jul;70(1):168-183. doi: 10.1002/hep.30347. Epub 2019 Mar 5.